0O59 Stock Overview
A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Sanofi Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €101.89 |
| 52 Week High | €106.14 |
| 52 Week Low | €80.62 |
| Beta | 0.42 |
| 11 Month Change | 0.48% |
| 3 Month Change | 13.14% |
| 1 Year Change | 0.35% |
| 33 Year Change | 23.35% |
| 5 Year Change | 23.96% |
| Change since IPO | 35.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0O59 | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -2.0% | -0.7% | 1.4% |
| 1Y | 0.3% | 4.2% | 8.1% |
Return vs Industry: 0O59 underperformed the UK Pharmaceuticals industry which returned 4.2% over the past year.
Return vs Market: 0O59 underperformed the UK Market which returned 8.1% over the past year.
Price Volatility
| 0O59 volatility | |
|---|---|
| 0O59 Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0O59 has not had significant price volatility in the past 3 months.
Volatility Over Time: 0O59's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 86,088 | Paul Hudson | www.sanofi.com |
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Sanofi Fundamentals Summary
| 0O59 fundamental statistics | |
|---|---|
| Market cap | €129.08b |
| Earnings (TTM) | €4.22b |
| Revenue (TTM) | €47.08b |
30.6x
P/E Ratio2.7x
P/S RatioIs 0O59 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0O59 income statement (TTM) | |
|---|---|
| Revenue | €47.08b |
| Cost of Revenue | €14.70b |
| Gross Profit | €32.38b |
| Other Expenses | €28.16b |
| Earnings | €4.22b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 25, 2024
| Earnings per share (EPS) | 3.36 |
| Gross Margin | 68.77% |
| Net Profit Margin | 8.96% |
| Debt/Equity Ratio | 29.8% |
How did 0O59 perform over the long term?
See historical performance and comparison